04Mar 2023
Improving Outcomes for Prostate Cancer Patients: The LUNAR Protocol

Improving Outcomes for Prostate Cancer Patients: The LUNAR Protocol

The LUNAR trial is a Phase 2 study to assess the efficacy and safety of neoadjuvant 177Lu‐PNT2002 plus stereotactic body radiotherapy (SBRT) vs SBRT alone in men with oligorecurrent metastatic hormone-sensitive prostate cancer. The trial aims to enroll 100 patients, and the primary endpoint is progression-free survival. The addition of 177Lu‐PNT2002 may potentially further forestall disease progression, and the results of this trial will determine the added benefit of 177Lu‐PNT2002 to SBRT in patients with oligorecurrent mHSPC.

  • #urology

Like

Save

Share